Is Ovid Therapeutics Inc. (OVID) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 10.8% / 30% | 39.0% / 30% | 0.0% / 30% | 689.05% / 5% | ✗ NOT HALAL |
| DJIM | 10.8% / 33% | 39.0% / 33% | 0.0% / 33% | 689.05% / 5% | ✗ NOT HALAL |
| MSCI | 16.0% / 33% | 57.6% / 33% | 0.0% / 33% | 689.05% / 5% | ✗ NOT HALAL |
| S&P | 10.8% / 33% | 39.0% / 33% | 0.0% / 33% | 689.05% / 5% | ✗ NOT HALAL |
| FTSE | 16.0% / 33% | 57.6% / 33% | 0.0% / 50% | 689.05% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -1712.1% | |
| Net Margin | -240.1% | |
| Return on Equity (ROE) | -17.5% | |
| Return on Assets (ROA) | -21.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$56M |
| Free Cash Flow | -$56M |
| Total Debt | $15M |
| Debt-to-Equity | 10.3 |
| Current Ratio | 9.0 |
| Total Assets | $92M |
Price & Trading
| Last Close | $2.46 |
| 50-Day MA | $1.79 |
| 200-Day MA | $1.31 |
| Avg Volume | 2.4M |
| Beta | 0.2 |
|
52-Week Range
$0.24
| |
About Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Ovid Therapeutics Inc. (OVID) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Ovid Therapeutics Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Ovid Therapeutics Inc.'s debt ratio?
Ovid Therapeutics Inc.'s debt ratio is 10.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 16.0%.
What are Ovid Therapeutics Inc.'s key financial metrics?
Ovid Therapeutics Inc. has a market capitalization of $347M, and revenue of $566,000. The company maintains a gross margin of 100.0% and a net margin of -240.1%. Return on equity stands at -17.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.